News
December 20, 2015
Emerging Health Technologies Can Enhance Canada’s Prosperity
Canadian pharmaceutical company Alpha Cancer Technologies Inc. is developing a way to deliver chemotherapy more effectively and with lower doses so the treatment does not cause toxicity in patients.
Read
May 28, 2014
PolyTherics and Alpha Cancer Technologies Collaborate to Produce Novel Drug Conjugates to Target Tumours
PolyTherics Limited (“PolyTherics”), an Abzena company that provides technologies and services to enable the development of better biopharmaceuticals, today announced a collaboration with Alpha Cancer Technologies Inc. (“ACT”), a Canadian company with a targeted drug delivery platform based on alpha fetoprotein (“AFP”). PolyTherics will produce a range of AFP drug conjugates for ACT to test using its proprietary ThioBridge™ technology.
Download
March 11, 2014
Alpha Cancer To Test Oncology Game Changer
AFP is a carrier protein known for transporting nutrients to rapidly growing fetal cells. Only trace amounts of the protein are found following birth, but importantly, receptors for AFP show up again on cancer cells to help shuttle nutrients to rapidly growing cancer cells.
Read
January 15, 2014
Strength From Within
Despite seemingly daily reports of the newest wonder drug that shrinks tumours, gene therapies or even a vaccine there really hasn’t been much progress treating the disease over the last half-century. In 1960, the mortality rate for all cancers combined in the United States was 194 deaths per 100,000 people. In 2009, the mortality rate was 174 deaths for every 100,000 persons.
Download
July 23, 2012
Treatment Without Side Effects
Alpha Cancer Technologies Inc. (ACT) has created an innovative approach to the advancement of cancer care. Increasing the quality of life is one of the key advantages of a new chemotherapy delivery system that the company is advancing.
Download
